Literature DB >> 15983773

Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.

Dong Joon Kim1, Dong Ik Kim, Seo Hyun Kim, Kyung Yeol Lee, Ji Hoe Heo, Sang Won Han.   

Abstract

The outcome of patients who show no early response to intravenous (i.v.) tissue plasminogen activator (tPA) therapy is poor. The objective of this study was to evaluate the feasibility of rescue localized intra-arterial thrombolysis (LIT) therapy for acute ischemic stroke patients after an early non-responsive i.v. tPA therapy. Patients with proximal MCA occlusions who were treated by LIT (n = 10) after failure of early response [no improvement or improvement of National Institute of Health Stroke Scale (NIHSS) scores of < or = 3] to i.v. tPA therapy (0.9 mg/kg-10% bolus and 90% i.v. infusion over 60 min) were selected. The recanalization rates, incidence of post-thrombolysis hemorrhage and clinical outcomes [baseline and discharge NIHSS scores, mortality, 3 months Barthel index (BI) and modified Rankin score (mRS)] were evaluated. Rescue LIT therapy was performed on ten MCA occlusion patients (male:female = 3:7, mean age 71 years). The mean time between the initiation of i.v. tPA therapy and the initiation of intra-arterial urokinase (i.a. UK) was 117+/-25.0 min [time to i.v. tPA 137+/-32 min; time to digital subtraction angiography (DSA) 221+/-42 min; time to i.a. UK 260+/-46 min]. The baseline NIHSS scores showed significant improvement at discharge (median from 18 to 6). Symptomatic hemorrhage and, consequent, mortality were noted in 2/10 (20%) patients. Three months good outcome was noted in 4/10 (40%, mRS 0-2) and 3/10 (30%, BI > or = 95). In conclusion, rescue LIT therapy can be considered as a treatment option for patients not showing early response to full dose i.v. tPA therapy. Larger scale studies for further validation of this protocol may be necessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983773     DOI: 10.1007/s00234-005-1388-2

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  26 in total

Review 1.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

2.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes.

Authors:  Jose I Suarez; Osama O Zaidat; Jeffrey L Sunshine; Robert Tarr; Warren R Selman; Dennis M D Landis
Journal:  Neurosurgery       Date:  2002-02       Impact factor: 4.654

4.  Inhibition of platelet aggregation by dialysable fibrinogen degradation products (FDP).

Authors:  J Stachurska; Z Latallo; M Kopeć
Journal:  Thromb Diath Haemorrh       Date:  1970-02-28

5.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

6.  Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis.

Authors:  Chelsea S Kidwell; Jeffrey L Saver; Joaquin Carneado; James Sayre; Sidney Starkman; Gary Duckwiler; Y Pierre Gobin; Reza Jahan; Paul Vespa; J Pablo Villablanca; David S Liebeskind; Fernando Vinuela
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion.

Authors:  Osama O Zaidat; Jose I Suarez; Concepcion Santillan; Jeffrey L Sunshine; Robert W Tarr; Vanessa H Paras; Warren R Selman; Dennis M D Landis
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

9.  Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase.

Authors:  J A Morris; D W Muller; E J Topol
Journal:  Am Heart J       Date:  1991-08       Impact factor: 4.749

10.  Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.

Authors:  J J Popma; R M Califf; S G Ellis; B S George; D J Kereiakes; J K Samaha; S J Worley; J L Anderson; D Stump; L Woodlief
Journal:  J Am Coll Cardiol       Date:  1992-11-15       Impact factor: 24.094

View more
  5 in total

Review 1.  The endovascular management of intracranial vascular disease including the MERCI device.

Authors:  Chirag D Gandhi; David M Johnson; Aman B Patel
Journal:  Curr Cardiol Rep       Date:  2007-03       Impact factor: 2.931

Review 2.  Intravenous rt-PA versus endovascular therapy for acute ischemic stroke.

Authors:  Pitchaiah Mandava; Jose I Suarez; Thomas A Kent
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

3.  Low-dose intra-arterial urokinase and aggressive mechanical clot disruption for acute ischemic stroke after failure of intravenous thrombolysis.

Authors:  W Yoon; M S Park; K H Cho
Journal:  AJNR Am J Neuroradiol       Date:  2009-08-27       Impact factor: 3.825

4.  The endovascular management of intracranial vascular disease including the MERCI device.

Authors:  Chirag D Gandhi; David M Johnson; Aman B Patel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-04

5.  Cerebral arterial calcification is an imaging prognostic marker for revascularization treatment of acute middle cerebral arterial occlusion.

Authors:  Seong-Joon Lee; Ji Man Hong; Manyong Lee; Kyoon Huh; Jin Wook Choi; Jin Soo Lee
Journal:  J Stroke       Date:  2015-01-30       Impact factor: 6.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.